Lantheus Holdings, Inc. (NASDAQ:LNTH) Position Boosted by Federated Hermes Inc.

Federated Hermes Inc. boosted its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 9.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 269,682 shares of the medical equipment provider's stock after purchasing an additional 24,326 shares during the period. Federated Hermes Inc. owned approximately 0.39% of Lantheus worth $21,653,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Silverberg Bernstein Capital Management LLC raised its position in shares of Lantheus by 0.4% in the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider's stock valued at $1,834,000 after purchasing an additional 100 shares in the last quarter. Moody National Bank Trust Division increased its stake in shares of Lantheus by 1.1% in the second quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider's stock worth $1,203,000 after buying an additional 162 shares during the last quarter. Shaker Investments LLC OH increased its stake in shares of Lantheus by 0.7% in the first quarter. Shaker Investments LLC OH now owns 27,962 shares of the medical equipment provider's stock worth $1,740,000 after buying an additional 182 shares during the last quarter. NBC Securities Inc. raised its holdings in Lantheus by 28.4% in the first quarter. NBC Securities Inc. now owns 863 shares of the medical equipment provider's stock valued at $53,000 after acquiring an additional 191 shares in the last quarter. Finally, GAMMA Investing LLC boosted its stake in Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock valued at $26,000 after acquiring an additional 208 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company's stock.

Insider Buying and Selling at Lantheus

In other Lantheus news, CAO Andrea Sabens sold 341 shares of Lantheus stock in a transaction on Monday, July 15th. The stock was sold at an average price of $123.15, for a total transaction of $41,994.15. Following the sale, the chief accounting officer now owns 62,216 shares of the company's stock, valued at approximately $7,661,900.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Lantheus news, CAO Andrea Sabens sold 341 shares of the business's stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $123.15, for a total transaction of $41,994.15. Following the sale, the chief accounting officer now directly owns 62,216 shares in the company, valued at approximately $7,661,900.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gary J. Pruden sold 12,530 shares of the stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $95.04, for a total transaction of $1,190,851.20. Following the completion of the transaction, the director now owns 11,978 shares of the company's stock, valued at $1,138,389.12. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 40,852 shares of company stock worth $3,922,001. 1.50% of the stock is owned by company insiders.

Lantheus Stock Performance

LNTH traded up $1.96 during trading on Monday, reaching $107.51. 449,086 shares of the company were exchanged, compared to its average volume of 1,025,087. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55. The firm has a 50 day moving average of $104.91 and a 200 day moving average of $82.86. The stock has a market cap of $7.46 billion, a P/E ratio of 16.11 and a beta of 0.50.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.68 by ($0.07). The firm had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The business's revenue was up 22.5% compared to the same quarter last year. During the same period last year, the firm posted $1.40 EPS. On average, sell-side analysts forecast that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. JMP Securities dropped their target price on shares of Lantheus from $130.00 to $125.00 and set a "market outperform" rating for the company in a research report on Thursday, August 1st. Redburn Atlantic initiated coverage on Lantheus in a research note on Tuesday, September 3rd. They set a "buy" rating and a $175.00 price objective on the stock. B. Riley lifted their target price on Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a research report on Thursday, July 25th. Truist Financial lowered their price target on Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a report on Thursday, August 1st. Finally, Leerink Partners raised their price objective on Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a research note on Thursday, July 11th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Lantheus currently has a consensus rating of "Moderate Buy" and a consensus price target of $126.00.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.